Measurand,count
 Factor II (Prothrombin) G20210A and Factor V Leiden G1691A point mutations in DNA,1
 single nucleotide variants (SNVs) and deletions in 23 genes from DNA and fusions in ROS1 from RNA,1
*1 (TA6) and *28 (TA7) alleles of the UDP glucuronosyltransferase 1A1 (UGT1A1) gene in genomic DNA,1
*2 and *3 CYP2C9 genetic variants and the VKORC1 3673 (-1639) intronic variant in genomic deoxyribonucleic acid (DNA),1
*2 and *3 alleles of the Verigene CYP2C9 gene locus and a single-point mutation (C to T at position 1173) of the VKORC1 gene locus,1
*2 and *3 alleles of the cytochrome P450 (CYP450) 2C9 gene locus and the Vitamin K epoxide reductase C1 (VKORC1) gene promoter polymorphism (-1639G>A) from genomic DNA ,1
"11 mutations in the phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) gene (Exon 7: C420R; Exon 9: E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R; and Exon 20: H1047L, H1047R, H1047Y)",2
139 clinically relevant cystic fibrosis disease‐causing mutations and variants of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in genomic DNA,1
185delAG and 5382insC variants in the BRCA1 gene and the 6174delT variant in the BRCA2 gene,1
"23 ACMG/ACOG mutations and the I506V, I507V, and F508C variants for deltaF508 ",1
"2C9*2, 2C9*3 alleles of the cytochrome P450 (CYP450) 2C9 gene locus and the Vitamin K epoxide reductase C1, VKORC1, gene promoter polymorphism (-1639) from genomic DNA",1
3 base pair nucleotide deletion (rs724159981) called the deltaE302/303 variant in the DYT1 gene,1
"56 specific mutations in RAS genes [KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4)] in DNA",1
70 gene expression profile ,1
BCR-ABL1 and ABL1 mRNA transcripts,1
BCR-ABL1 and ABL1 transcripts in total RNA,2
BCR-ABL1 transcripts (e13a2/b2a2 and/or e14a2/b3a2) and the ABL1 endogenous control mRNA,1
BLMAsh variant in the BLM gene,1
BRAF V600E and V600K mutations in DNA,1
BRAF V600E mutation in DNA,2
BRCA1 and BRCA2 alterations,1
C282Y (rs1800562) and H63D (rs1799945) variants in the HFE gene,1
CYP2C19 genotype from genomic DNA,1
"CYP2C19, CYP2C9, CYP3A5, UGT1A1, DPYD, TPMT, SLCO1B1, CYP2D6 variants",2
CYP450 2C19 genotype in genomic deoxyribonucleic acid (DNA),2
"Exon 18: G719X (G719A, G719C, and G719S); Exon 19: deletions and complex mutations (defined as the combination of a deletion and an insertion); Exon 20: S768I, T790M, and insertions;  Exon 21: L858R and L861Q",2
Factor II (G2021 OA) and Factor V Leiden (G1691A) mutations,1
"Factor II (Prothrombin) G20210A mutation, from DNA; single point mutation (G to A at position 20210) ofthe human Factor II gene from DNA, Factor II DNA",1
"Factor II (Prothrombin) G20210A, Factor V (Factor V Leiden) G1691A and MTHFR (human 5, 10 methylenetetrahydro- folate reductase gene) C677T and A1298C mutations; Factor II (Prothrombin) G20210A and Factor V (Factor V Leiden) G1691A mutations in patients with suspected thrombophilia from isolated genomic DNA; single point mutation (G to A at position 1691; also known as Factor V Leiden) of the human Factor V gene (FV; Coagulation Factor V gene) from isolated genomic DNA ; single point mutation (G to A at position 20210 of the human Factor II gene (FII; prothrombin gene)from isolated genomic DNA; point mutations (C to T at position 677) and (A to C at position 1298) of the human 5, 10 methylenetetrahydrofolate reductase gene (MTHFR) from isolated genomic DNA",1
Factor V Leiden G1691A and Factor II (Prothrombin) G20210A point mutations in DNA,1
Factor V Leiden variant in the F5 gene,1
Gene expression profile for 15 common tumor types ,3
HER-2/neu gene amplification,2
HER2 gene amplification,3
HER2 gene amplification status by enumeration of the ratio of the HER2 gene to chromosome 17,2
HER2 gene and centromeric region of chromosome 17,1
HER2 overexpression,1
HLA-DQ2.5 haplotype (rs2187668) in the HLA-DQA1 gene,1
JAK2 V617F/G1849T allele in genomic DNA,2
KIT d816v mutational status,1
LSI D7S486 probe target on chromosome 7q31 and the CEP 7 probe target on chromosome 7p11.1-q11.1,1
LSI EGR1 probe target on chromosome 5q,2
"MLH1, MSH2 and MSH6, and PMS2 ",1
"MMR proteins MLH1, PMS2, MSH2 and MSH6 and mutated BRAF V600E protein",1
N-Myc Downstream-Regulated Gene 4 (NDRG4) and the Bone Morphogenetic Protein 3 (BMP3); v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) gene; hemoglobin,1
No record,2
T-Cell Receptor Excision Circles (TRECs),1
The system has been validated for the detection of SNVs and up to 3 base deletions.,1
Total Prostate specific antigen (tPSA) ,1
Y179C and the G396D variants in the MUTYH gene,1
a single point mutation (G to A at position 20210) of the human Factor 11 gene in isolated genomic DNA,1
alpha satellite sequences in the centromere regions,1
amplifications and deletions (copy number changes) of the TOP2A gene,1
"aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus",1
chromosome 8 in both interphase nuclei and metaphase spreads,1
chromosomes X and Y in both interphase nuclei and metaphase spreads,1
concentration of prostate cancer gene 3 (PCA3) and prostate-specific antigen (PSA) RNA (RNA) molecules ,1
copy number variations (CNV) and copy-neutral loss of heterozygosity (cnLOH),2
"counting of Hematopoietic cells and Amniotic cells; Aneuploidy for chromosomes 3,7, 17 and loss of the 9p21 locus; chromosome 17 and the HER-2/neu gene; rearrangements involving the ALK gene",1
"deletion of mononucleotides in 5 microsatellite loci (BAT-25, BAT-26, NR-21, NR-24 and MONO-27) using matched tumor and normal DNA",1
deletion of the LSI TP53 probe target (17p-),1
"deletion of the LSI TP53, LSI ATM, and LSI D13S319 probe targets and gain of the D12Z3 sequence",1
detection and quantification of chromosome 12 in interphase nuclei ,1
exon 19 deletions and exon 21 (L858R) substitution mutations ofthe epidermal growth factor receptor (EGFR) gene,3
fluorescence signals of labeled nucleotides,1
genetic variants in a DNA ,1
greater than 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies ,1
human DNA,1
internal tandem duplication (ITD) mutations and the tyrosine kinase domain mutations D835 and I836 in the FLT3 gene in genomic DNA,1
methylated Septin 9 DNA in EDTA plasma,1
multiple mutations and/or polymorphisms in an amplified DNA,1
number of cytosine-guanine-guanine (CGG) repeats in the fragile X mental retai·dation-1 (FMRl) gene,1
over-expression of her-2/neu,1
panel of 24 cystic fibrosis mutations from DNA,1
panel of mutations and variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene,8
panel of nucleotide variants found within the highly polymorphic CYP2D6 gene located on chromosome 22 from genomic DNA,2
pdgfrb gene rearrangement,1
presence of CYP2C9 *2 and *3 and VKORC1 1173 C>T alleles,1
"rearranged IgH (VDJ), IgH (DJ), IgK and IgL receptor gene sequences, as well as translocated BCL1/IgH (J) and BCL2/IgH (J) sequences in DNA",2
rearrangement of the MLL (KMT2A) region on chromosome 11 at location 11q23.3; deletion of the P53 (TP53) region on chromosome 7 at location 17p13; deletion within the long arm of chromosome 20 at locations 20q12 and 20q13.1; rearrangement of the chromosome 16 causing the CBFβ- MYH11 (CBFB-MYH11) fusion; deletions within the long arm of chromosome 5 at location 5q31.2 in fixed; deletions within the long arm of chromosome 7 at locations 7q22 and 7q31.2; rearrangement involving the AML1 (RUNX1) region on chromosome 21 at location 21q22.1 and the ETO (RUNX1T1) region on chromosome 8 at location 8q21.3;  rearrangement involving the EVI1 (MECOM) region on chromosome 3 at location 3q26.2 in fixed bone marrow,1
rearrangements involving the ALK gene ,1
seven somatic mutations in codons 12 and 13 of the KRAS gene in DNA,2
"single nucleotide mutations for Y646N, Y646F or Y646X (Y646H, Y646S, or Y646C), A682G, and A692V of the EZH2 gene in DNA ",1
single nucleotide polymorphism detection of Factor V Leiden variant in the F5 gene (rs6025) and Prothrombin G20210A variant in the F2 gene (rs1799963/i3002432),1
single nucleotide polymorphism detection of G2019S (rs34637584) variant in the LRRK2 gene and N370S (rs76763715) variant in the GBA gene,1
single nucleotide polymorphism detection of epsilon-4 (rs429358) variant in the APOE gene,1
"single nucleotide polymorphism detection of the F283L (rs121965064), E117X (rs121965063), and IVS14+1G>A (rs373297713) variants in the FXI gene",1
"single nucleotide polymorphism detection of the N370S (rs76763715) variant, 84GG (rs387906315) variant and V394L (rs80356769) variant in the GBA gene",1
single nucleotide polymorphism detection of the PI*Z (rs28929474) and PI*S (rs17580) variants in the SERPINA1 gene,1
single nucleotide polymorphism detection of the Val68Met (rs1050828) variant in the G6PD gene,1
single nucleotide variants (SNVs) and deletions in 2 genes from DNA,1
"single nucleotide variants (SNVs) coding five IDH1 R132 mutations (R132C, R132H, R132G, R132S, and R132L)",1
"single nucleotide variants (SNVs) coding nine IDH2 mutations (R140Q, R140L, R140G, R140W, R172K, R172M, R172G, R172S, and R172W)",1
"single nucleotide variants (SNVs), insertions, deletions (indels) in 55 genes, copy number amplifications (CNAs) in two (2) genes, and fusions in four (4) genes. Guardant360 CDx utilizes circulating cell-free DNA (cfDNA) from plasma ",1
"single nucleotide variants, and small InDels within the region sequenced",1
"single nucleotide variants, insertions and deletions, and large rearrangement variants in protein coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes and the determination of Genomic Instability Score (GIS) which is an algorithmic measurement of Loss of Heterozygosity (LOH), Telomeric Allelic Imbalance (TAI), and Large-scale State Transitions (LST) using DNA",1
"single point mutation (A to C at position 1298) of the human 5,10- methylenetetrahydrofolate reductase (MTHFR) gene in isolated genornic DNA",1
"single point mutation (C to T at position 677) of the human 5, 10- methylenetetrahydrofolate reductase (MTHFR) gene in isolated genomic DNA",1
single point mutation (G to A at position 1691) of the human Factor V gene in isolated genomic DNA,1
"single point mutation (G to A at position 1691; also known as Factor V Leiden) of the human Factor V gene (F5; Coagulation Factor V gene) ; single point mutation (G to A at position 20210) of the human Factor IIgene (F2; prothrombin gene) ; single point mutation (C to T at position 677) of the human 5,10 methylenetetrahydrofolate reductase gene (MTHFR) from isolated genomic DNA",1
"single point mutation (G1691A, referred to as the Factor V Leiden mutation or FVL) of the Factor V gene, located on Chromosome 1q23, and a single point mutation (G20210A) of the prothrombin gene (referred to as Factor II or FII), located on Chromosome 11p11-q12, from genomic DNA",1
"somatic single nucleotide variants, insertions, deletions (indels) smaller than 35 bp, in human genomic DNA  tumor gene alterations in a 607-gene panel",1
"somatic single nucleotide variants, insertions, deletions, and microsatellite instability in genes in human genomic DNA ",1
"somatic single nucleotide variants, insertions, deletions, and tumor mutational burden (TMB) in human genomic DNA",1
"somatic single nucleotide variants, insertions, deletions, select amplifications and translocations, microsatellite instability (MSI) and tumor mutation burden (TMB) in human genomic DNA",1
"substitutions, insertion, deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA",1
"substitutions, insertions and deletions (indels) in 311 genes, including rearrangements and copy number losses only in BRCA1 and BRCA2",1
"substitutions, insertions, deletions (indels) in 311 genes, including rearrangements in three (3) genes, and copy number alterations in three (3) genes",1
the messenger RNA transcribed from 58 genes,1
two RNA transcripts (PLA2G7 and PLAC8) using total RNA ,1
"two point mutations in exon 7 [p.R248C (c.742C>T), p.S249C (c.746C>G)], two point mutations in exon 10 [p.G370C (c.1108G>T) and p.Y373C (c.1118A>G)] and two fusions (FGFR3-TACC3v1 and FGFR3-TACC3v3) in the fibroblast growth factor receptor 3 (FGFR3) gene in RNA ",1
"two single nucleotide polymorphisms (SNP) in the cytochrome P450 enzyme gene CYP2C9 known as CYP2C9*2 (C430T) and CYP2C9*3 (A1075C), and a SNP in the vitamin K epoxide reductase complex 1 gene VKORC1, known as VKORC1 (–1639G>A)",1
venous whole blood,1
